Georges Ferdinand Randriafanomezantsoa Radohery

@inrae.fr

Fruit Biology and Pathology
INRAE



           

https://researchid.co/research_id_grandriafan

RESEARCH, TEACHING, or OTHER INTERESTS

Modeling and Simulation, Plant Science, Pharmacology (medical)

4

Scopus Publications

Scopus Publications

  • Parasite Viability as a Measure of in Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
    Georges F. R. Radohery, Annabelle Walz, Christin Gumpp, Mohammed H. Cherkaoui-Rbati, Nathalie Gobeau, Jeremy Gower, Miles P. Davenport, Matthias Rottmann, James S. McCarthy, Jörg J. Möhrle,et al.
    American Society for Microbiology
    The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this metric does not distinguish between viable and nonviable parasites. Thus, enumeration of parasites may result in underestimation of drug activity for some compounds, potentially confounding its use as a metric for assessing antimalarial activity in vivo . Here, we report a study of the effect of artesunate on Plasmodium falciparum viability in humans and in mice.

  • Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
    Georges F R Radohery, Jeremy Gower, Bridget E Barber, Kevinkumar Kansagra, Jörg J Möhrle, Miles P Davenport, James S McCarthy, David S Khoury, and Maria Rebelo
    Elsevier BV

  • Within-host modeling of blood-stage malaria
    David S. Khoury, Rosemary Aogo, Georges Randriafanomezantsoa‐Radohery, James M. McCaw, Julie A. Simpson, James S. McCarthy, Ashraful Haque, Deborah Cromer, and Miles P. Davenport
    Wiley
    SummaryMalaria infection continues to be a major health problem worldwide and drug resistance in the major human parasite species, Plasmodium falciparum, is increasing in South East Asia. Control measures including novel drugs and vaccines are in development, and contributions to the rational design and optimal usage of these interventions are urgently needed. Infection involves the complex interaction of parasite dynamics, host immunity, and drug effects. The long life cycle (48 hours in the common human species) and synchronized replication cycle of the parasite population present significant challenges to modeling the dynamics of Plasmodium infection. Coupled with these, variation in immune recognition and drug action at different life cycle stages leads to further complexity. We review the development and progress of “within‐host” models of Plasmodium infection, and how these have been applied to understanding and interpreting human infection and animal models of infection.

  • 2-designs and codes from certain 2-transitive simple groups